Control Bionics (ASX: CBL) registers NeuroStrip with US FDA as commercial execution becomes the next test
Read More Pharma Industry News Jazz Pharmaceuticals (JAZZ) builds $4bn oncology option through AbCellera partnership Jazz could pay AbCellera more than $4 billion across five oncology programmes. Read how the option deal reshapes JAZZ and ABCL growth strategies. byVenkateshJune 22, 2026